IO Biotech shares are trading lower after the company increased the enrolled patients in Phase 3 trial to 380, potentially accelerating the time to reach the primary end point of progression free survival
Portfolio Pulse from Benzinga Newsdesk
IO Biotech's shares are trading lower after the company increased the enrolled patients in its Phase 3 trial to 380, potentially accelerating the time to reach the primary end point of progression-free survival.

June 14, 2023 | 1:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IO Biotech's stock price is trading lower due to the increase in enrolled patients in its Phase 3 trial, potentially accelerating the time to reach the primary end point.
IO Biotech's decision to increase the number of enrolled patients in its Phase 3 trial may lead to faster results, but it also increases the uncertainty and risk associated with the trial. This has led to a decrease in the stock price as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100